# Tachycardia â€“ RRT Protocol with Virtua Voorhees Addenda

**Primary Guideline:** American Heart Association (AHA) Advanced Cardiovascular Life Support (ACLS) 2020 Guidelines (Current through 2025)
**Official Source:** https://cpr.heart.org/en/resuscitation-science/cpr-and-ecc-guidelines/adult-advanced-cardiovascular-life-support
**Supporting Guidelines:**
- 2019 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation
- 2017 AHA/ACC/HRS Guideline for the Management of Patients with Ventricular Arrhythmias

## ENHANCED MERMAID FLOWCHART ALGORITHM

~~~mermaid
graph TD
    A["Tachycardia Recognition<br/>HR >150 bpm + Symptoms"] --> B{"Patient<br/>Stable?"}
    
    B -->|UNSTABLE| C["Synchronized Cardioversion<br/>Sedate if Conscious"]
    B -->|STABLE| D["12-Lead ECG Analysis<br/>Identify Rhythm"]
    
    C --> E["Post-Cardioversion<br/>Monitor & Evaluate"]
    D --> F{"QRS Width<br/>Assessment?"}
    
    F -->|"NARROW <120ms"| G{"Rhythm<br/>Regularity?"}
    F -->|"WIDE â‰¥120ms"| H["Assume VT Until<br/>Proven Otherwise"]
    
    G -->|REGULAR| I["Vagal Maneuvers<br/>+ Adenosine 6-12mg"]
    G -->|IRREGULAR| J["Atrial Fibrillation<br/>Rate Control"]
    
    H --> K["Stable VT<br/>Antiarrhythmic Therapy"]
    
    I --> L{"SVT<br/>Converted?"}
    J --> M["Diltiazem/Metoprolol<br/>Target HR <110"]
    K --> N["Amiodarone 150mg<br/>or Procainamide"]
    
    L -->|YES| O["Monitor & Treat<br/>Underlying Cause"]
    L -->|NO| P["Beta-Blocker or<br/>Calcium Channel Blocker"]
    
    M --> Q["Consider Anticoagulation<br/>CHA2DS2-VASc Score"]
    N --> R["Assess Response<br/>& Stability"]
    P --> O
    
    E --> O
    O --> S["Disposition<br/>Telemetry/ICU"]
    Q --> S
    R --> S
    
    style A fill:#ffcccc
    style B fill:#ffe6cc
    style C fill:#ffaaaa
    style I fill:#fff2cc
    style J fill:#ccffcc
    style K fill:#e6ccff
    style S fill:#ccffee
~~~

## STREAMLINED DYNAMIC CARD SYSTEM

### Card 0 â€“ Tachycardia Recognition & Stability Assessment (Node A â†’ B)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸš¨ TACHYCARDIA RRT ACTIVATION            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸ“Š Recognition criteria:                â”‚
â”‚ â€¢ Heart rate >150 bpm (sustained)      â”‚
â”‚ â€¢ Associated symptoms present           â”‚
â”‚ â€¢ Hemodynamic compromise possible       â”‚
â”‚                                         â”‚
â”‚ ðŸš¨ Instability indicators (ANY = unstable):â”‚
â”‚ â€¢ Hypotension (SBP <90 mmHg)           â”‚
â”‚ â€¢ Altered mental status                â”‚
â”‚ â€¢ Signs of shock (poor perfusion)      â”‚
â”‚ â€¢ Ischemic chest discomfort            â”‚
â”‚ â€¢ Acute heart failure                  â”‚
â”‚                                         â”‚
â”‚ ðŸš€ Immediate actions:                   â”‚
â”‚ â€¢ 12-lead ECG                          â”‚
â”‚ â€¢ IV access Ã— 2                        â”‚
â”‚ â€¢ Continuous monitoring                â”‚
â”‚ â€¢ Defibrillator at bedside             â”‚
â”‚                                         â”‚
â”‚ â“ Patient hemodynamically stable?      â”‚
â”‚                                         â”‚
â”‚ ðŸ”˜ YES â†’ Rhythm analysis               â”‚
â”‚ ðŸ”˜ NO â†’ Immediate cardioversion        â”‚
â”‚                                         â”‚
â”‚ [Next: Based on Selection â–¶]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1A â€“ Synchronized Cardioversion (Node C â†’ E)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš¡ SYNCHRONIZED CARDIOVERSION            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸš¨ Unstable tachycardia protocol:       â”‚
â”‚ â€¢ Immediate intervention required       â”‚
â”‚ â€¢ Do not delay for medication trials   â”‚
â”‚                                         â”‚
â”‚ ðŸ’Š Pre-cardioversion sedation:          â”‚
â”‚ â€¢ Midazolam 2-5mg IV if conscious      â”‚
â”‚ â€¢ Propofol 0.5-1mg/kg if available     â”‚
â”‚ â€¢ Maintain airway support              â”‚
â”‚                                         â”‚
â”‚ âš¡ Energy recommendations:               â”‚
â”‚ â€¢ Narrow regular: 50-100J              â”‚
â”‚ â€¢ Narrow irregular (A-fib): 120-200J   â”‚
â”‚ â€¢ Wide complex: 100J, then 150J, 200J  â”‚
â”‚                                         â”‚
â”‚ ðŸ”§ Procedure checklist:                 â”‚
â”‚ â€¢ Sync mode ON                         â”‚
â”‚ â€¢ Proper pad placement                 â”‚
â”‚ â€¢ "Clear" before shock                 â”‚
â”‚                                         â”‚
â”‚ [Next: Post-cardioversion care â–¶]      â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Stability Assessment]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 1B â€“ Rhythm Analysis (Node D â†’ F)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸ“Š 12-LEAD ECG RHYTHM ANALYSIS          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸ” Systematic approach:                 â”‚
â”‚ â€¢ Rate: >150 bpm confirmed             â”‚
â”‚ â€¢ Rhythm: Regular vs irregular          â”‚
â”‚ â€¢ QRS width: <120ms vs â‰¥120ms          â”‚
â”‚ â€¢ P waves: Present, absent, or abnormalâ”‚
â”‚                                         â”‚
â”‚ ðŸ“‹ Classification system:               â”‚
â”‚ â€¢ Narrow complex + regular = SVT       â”‚
â”‚ â€¢ Narrow complex + irregular = A-fib   â”‚
â”‚ â€¢ Wide complex = VT until proven otherwiseâ”‚
â”‚                                         â”‚
â”‚ â“ QRS width measurement?               â”‚
â”‚                                         â”‚
â”‚ ðŸ”˜ NARROW (<120ms) â†’ Assess regularity â”‚
â”‚ ðŸ”˜ WIDE (â‰¥120ms) â†’ Assume VT           â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2A â€“ SVT Management (Node I â†’ L)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸ«€ SUPRAVENTRICULAR TACHYCARDIA         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸŽ¯ Narrow complex regular tachycardia:  â”‚
â”‚ â€¢ AVNRT (most common)                  â”‚
â”‚ â€¢ AVRT (accessory pathway)             â”‚
â”‚ â€¢ Atrial flutter with 2:1 conduction   â”‚
â”‚                                         â”‚
â”‚ ðŸ¤² Vagal maneuvers (try first):        â”‚
â”‚ â€¢ Valsalva maneuver (15 seconds)       â”‚
â”‚ â€¢ Carotid sinus massage (if no bruit)  â”‚
â”‚ â€¢ Ice water immersion                  â”‚
â”‚                                         â”‚
â”‚ ðŸ’‰ Adenosine protocol:                  â”‚
â”‚ â€¢ First dose: 6mg rapid IV push        â”‚
â”‚ â€¢ Second dose: 12mg if no response     â”‚
â”‚ â€¢ Third dose: 12mg if needed           â”‚
â”‚ â€¢ Give through large-bore peripheral IVâ”‚
â”‚                                         â”‚
â”‚ âš ï¸ Contraindications:                   â”‚
â”‚ â€¢ Known WPW with A-fib                 â”‚
â”‚ â€¢ Asthma (relative)                    â”‚
â”‚ â€¢ Heart transplant recipients          â”‚
â”‚                                         â”‚
â”‚ [Next: Conversion assessment â–¶]        â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: QRS Analysis]             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2B â€“ Atrial Fibrillation Management (Node J â†’ M)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸ«€ ATRIAL FIBRILLATION WITH RVR         â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸŽ¯ Rate control strategy:               â”‚
â”‚ â€¢ Target: <110 bpm at rest             â”‚
â”‚ â€¢ Avoid aggressive rate control        â”‚
â”‚ â€¢ Monitor for conversion to NSR        â”‚
â”‚                                         â”‚
â”‚ ðŸ’Š First-line agents:                   â”‚
â”‚                                         â”‚
â”‚ ðŸ”¸ Diltiazem (preferred):               â”‚
â”‚ â€¢ Loading: 0.25mg/kg IV over 2 min     â”‚
â”‚ â€¢ Second dose: 0.35mg/kg if needed     â”‚
â”‚ â€¢ Infusion: 5-15mg/hr                  â”‚
â”‚                                         â”‚
â”‚ ðŸ”¸ Metoprolol:                          â”‚
â”‚ â€¢ 2.5-5mg IV every 5 minutes           â”‚
â”‚ â€¢ Maximum: 15mg total                  â”‚
â”‚ â€¢ Avoid in acute heart failure         â”‚
â”‚                                         â”‚
â”‚ ðŸ”¸ Amiodarone (low EF):                 â”‚
â”‚ â€¢ 150mg IV over 10 minutes             â”‚
â”‚ â€¢ Then 1mg/min Ã— 6hr, then 0.5mg/min  â”‚
â”‚                                         â”‚
â”‚ [Next: Anticoagulation assessment â–¶]   â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: QRS Analysis]             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 2C â€“ Wide Complex Tachycardia (Node K â†’ N)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ âš¡ WIDE COMPLEX TACHYCARDIA (VT)        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸš¨ Assume VT until proven otherwise:    â”‚
â”‚ â€¢ Most wide complex tachycardia is VT  â”‚
â”‚ â€¢ Don't waste time on differential     â”‚
â”‚ â€¢ Treat aggressively                   â”‚
â”‚                                         â”‚
â”‚ ðŸ’Š Antiarrhythmic therapy:              â”‚
â”‚                                         â”‚
â”‚ ðŸ”¸ Amiodarone (first-line):             â”‚
â”‚ â€¢ 150mg IV over 10-20 minutes          â”‚
â”‚ â€¢ May repeat Ã— 1 if needed             â”‚
â”‚ â€¢ Then maintenance infusion            â”‚
â”‚                                         â”‚
â”‚ ðŸ”¸ Procainamide (alternative):          â”‚
â”‚ â€¢ 20-50mg/min IV infusion              â”‚
â”‚ â€¢ Maximum: 17mg/kg total dose          â”‚
â”‚ â€¢ Monitor for hypotension              â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Avoid these in VT:                   â”‚
â”‚ â€¢ Adenosine                            â”‚
â”‚ â€¢ Calcium channel blockers             â”‚
â”‚ â€¢ Beta-blockers                        â”‚
â”‚                                         â”‚
â”‚ [Next: Response assessment â–¶]          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: QRS Analysis]             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3A â€“ SVT Conversion Assessment (Node L)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸ”„ SVT CONVERSION EVALUATION            â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸ“Š Success indicators:                  â”‚
â”‚ â€¢ Abrupt termination to sinus rhythm   â”‚
â”‚ â€¢ Heart rate <100 bpm                  â”‚
â”‚ â€¢ Symptom resolution                   â”‚
â”‚                                         â”‚
â”‚ ðŸ“ˆ Failure indicators:                  â”‚
â”‚ â€¢ Persistent tachycardia               â”‚
â”‚ â€¢ Rate unchanged after adenosine       â”‚
â”‚ â€¢ Continued symptoms                   â”‚
â”‚                                         â”‚
â”‚ â“ SVT successfully converted?          â”‚
â”‚                                         â”‚
â”‚ ðŸ”˜ YES â†’ Investigate underlying cause  â”‚
â”‚ ðŸ”˜ NO â†’ Alternative rate control agentsâ”‚
â”‚                                         â”‚
â”‚ ðŸ’¡ If unsuccessful:                     â”‚
â”‚ â€¢ Consider beta-blocker                â”‚
â”‚ â€¢ Consider calcium channel blocker     â”‚
â”‚ â€¢ Reassess for atrial flutter          â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous] [Next: Based on Selection â–¶]â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 3B â€“ Alternative Rate Control (Node P â†’ O)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸ’Š ALTERNATIVE RATE CONTROL             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸ”¸ Metoprolol protocol:                 â”‚
â”‚ â€¢ 5mg IV every 5 minutes               â”‚
â”‚ â€¢ Maximum: 15mg total                  â”‚
â”‚ â€¢ Monitor BP and signs of CHF          â”‚
â”‚                                         â”‚
â”‚ ðŸ”¸ Diltiazem protocol:                  â”‚
â”‚ â€¢ 0.25mg/kg IV over 2 minutes          â”‚
â”‚ â€¢ May repeat 0.35mg/kg in 15 minutes   â”‚
â”‚ â€¢ Start infusion 5-15mg/hr             â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Contraindications:                   â”‚
â”‚ â€¢ Hypotension                          â”‚
â”‚ â€¢ Severe heart failure                 â”‚
â”‚ â€¢ Heart block                          â”‚
â”‚ â€¢ WPW syndrome                         â”‚
â”‚                                         â”‚
â”‚ [Next: Monitor response â–¶]             â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: SVT Conversion]           â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 4A â€“ Anticoagulation Assessment (Node Q â†’ S)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸ©¸ ANTICOAGULATION EVALUATION           â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸ“Š CHA2DS2-VASc Score calculation:      â”‚
â”‚ â€¢ Congestive heart failure (1 pt)      â”‚
â”‚ â€¢ Hypertension (1 pt)                  â”‚
â”‚ â€¢ Age â‰¥75 years (2 pts)                â”‚
â”‚ â€¢ Diabetes mellitus (1 pt)             â”‚
â”‚ â€¢ Stroke/TIA history (2 pts)           â”‚
â”‚ â€¢ Vascular disease (1 pt)              â”‚
â”‚ â€¢ Age 65-74 years (1 pt)               â”‚
â”‚ â€¢ Sex category (female = 1 pt)         â”‚
â”‚                                         â”‚
â”‚ ðŸŽ¯ Anticoagulation recommendations:     â”‚
â”‚ â€¢ Score 0 (males) or 1 (females): None â”‚
â”‚ â€¢ Score 1 (males): Consider            â”‚
â”‚ â€¢ Score â‰¥2: Recommended                â”‚
â”‚                                         â”‚
â”‚ ðŸ’Š Anticoagulation options:             â”‚
â”‚ â€¢ Warfarin (INR 2-3)                   â”‚
â”‚ â€¢ Direct oral anticoagulants (DOACs)   â”‚
â”‚ â€¢ Consider bleeding risk (HAS-BLED)    â”‚
â”‚                                         â”‚
â”‚ [Next: Disposition planning â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: A-fib Management]         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 5A â€“ VT Response Assessment (Node R â†’ S)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸ“Š VT TREATMENT RESPONSE                â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ âœ… Successful treatment indicators:      â”‚
â”‚ â€¢ Conversion to sinus rhythm           â”‚
â”‚ â€¢ Significant rate reduction           â”‚
â”‚ â€¢ Hemodynamic improvement              â”‚
â”‚ â€¢ Symptom resolution                   â”‚
â”‚                                         â”‚
â”‚ âš ï¸ Treatment failure indicators:         â”‚
â”‚ â€¢ Persistent wide complex tachycardia  â”‚
â”‚ â€¢ Hemodynamic deterioration            â”‚
â”‚ â€¢ Recurrent episodes                   â”‚
â”‚                                         â”‚
â”‚ ðŸš¨ If treatment fails:                  â”‚
â”‚ â€¢ Consider synchronized cardioversion  â”‚
â”‚ â€¢ Reassess stability                   â”‚
â”‚ â€¢ Alternative antiarrhythmic agents    â”‚
â”‚ â€¢ Cardiology consultation              â”‚
â”‚                                         â”‚
â”‚ [Next: Disposition planning â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: VT Management]            â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 6 â€“ Underlying Cause Investigation (Node O â†’ S)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸ” UNDERLYING CAUSE EVALUATION          â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸ©º Common precipitating factors:        â”‚
â”‚ â€¢ Acute coronary syndrome              â”‚
â”‚ â€¢ Electrolyte abnormalities            â”‚
â”‚ â€¢ Hyperthyroidism                      â”‚
â”‚ â€¢ Pulmonary embolism                   â”‚
â”‚ â€¢ Medication effects                   â”‚
â”‚                                         â”‚
â”‚ ðŸ“Š Diagnostic workup:                   â”‚
â”‚ â€¢ Basic metabolic panel                â”‚
â”‚ â€¢ Thyroid function tests               â”‚
â”‚ â€¢ Cardiac enzymes/troponins            â”‚
â”‚ â€¢ Chest X-ray                          â”‚
â”‚ â€¢ Echocardiogram if indicated          â”‚
â”‚                                         â”‚
â”‚ ðŸ’Š Address reversible causes:           â”‚
â”‚ â€¢ Correct electrolyte abnormalities    â”‚
â”‚ â€¢ Treat underlying conditions          â”‚
â”‚ â€¢ Adjust medications                   â”‚
â”‚                                         â”‚
â”‚ [Next: Disposition planning â–¶]         â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Treatment Pathways]       â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

### Card 7 â€“ Disposition & Monitoring (Node S - Final)
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ðŸ¥ DISPOSITION & FOLLOW-UP              â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚ ðŸ“ Disposition options:                 â”‚
â”‚                                         â”‚
â”‚ ðŸ”´ ICU admission:                       â”‚
â”‚ â€¢ Unstable tachycardia requiring cardioversionâ”‚
â”‚ â€¢ Antiarrhythmic infusions             â”‚
â”‚ â€¢ Hemodynamic monitoring needed        â”‚
â”‚                                         â”‚
â”‚ ðŸŸ¡ Telemetry monitoring:                â”‚
â”‚ â€¢ Stable arrhythmias                   â”‚
â”‚ â€¢ New-onset atrial fibrillation        â”‚
â”‚ â€¢ Medication titration                 â”‚
â”‚                                         â”‚
â”‚ ðŸŸ¢ Medical floor:                       â”‚
â”‚ â€¢ Well-controlled atrial fibrillation  â”‚
â”‚ â€¢ Converted SVT with known trigger     â”‚
â”‚ â€¢ Stable after treatment               â”‚
â”‚                                         â”‚
â”‚ ðŸ“‹ Follow-up coordination:              â”‚
â”‚ â€¢ Cardiology: 1-2 weeks for new onset â”‚
â”‚ â€¢ Primary care: 1 week                 â”‚
â”‚ â€¢ Electrophysiology if recurrent       â”‚
â”‚                                         â”‚
â”‚ âœ… DISPOSITION PROTOCOL COMPLETE       â”‚
â”‚                                         â”‚
â”‚ [â—€ Previous: Treatment Completion]     â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜

## VIRTUA VOORHEES TACHYCARDIA ADDENDA

### **Enhanced RRT Response Program:**
- **Rapid Response Team:** Immediate multidisciplinary activation including critical care and cardiology
- **Equipment Availability:** Defibrillators with cardioversion capability on all RRT carts
- **Pharmacy Support:** Pre-drawn emergency medications (adenosine, diltiazem, amiodarone)
- **Quality Metrics:** Time to rhythm identification, cardioversion success rates, complications

### **Updated ACLS Integration:**
**Adenosine Administration Updates:**
- **Rapid push technique:** Give through most proximal port followed by immediate saline flush
- **Half-life awareness:** <10 seconds, effects seen within 15-30 seconds
- **Monitoring:** Continuous telemetry during administration

**Rate Control Optimization:**
- **Diltiazem preferred:** Better efficacy and safety profile than verapamil
- **Weight-based dosing:** 0.25mg/kg then 0.35mg/kg with infusion titration
- **Avoid in WPW:** Can accelerate ventricular response in pre-excited A-fib

### **Advanced Monitoring Capabilities:**
- **Continuous telemetry:** Real-time rhythm analysis with arrhythmia detection
- **12-lead ECG integration:** Automatic rhythm interpretation with alerts
- **Hemodynamic monitoring:** Blood pressure trending during rate control
- **Drug response tracking:** Medication effectiveness documentation

### **Cardiology Integration:**
**24/7 Availability:**
- **General cardiology:** For complex arrhythmia management
- **Electrophysiology:** For refractory cases and ablation candidates
- **Transfer Center:** 856-886-5111 for specialized interventions

**Anticoagulation Program:**
- **Pharmacy-driven protocols:** CHA2DS2-VASc and HAS-BLED score integration
- **DOAC preferred:** Unless contraindicated or patient preference
- **Bridging protocols:** For procedures in anticoagulated patients

### **Special Population Considerations:**
**Wolff-Parkinson-White Syndrome:**
- **Recognize pre-excitation:** Delta waves, short PR interval
- **Avoid AV nodal blockers:** Can precipitate VF in A-fib with WPW
- **Procainamide preferred:** For wide complex tachycardia in WPW

**Heart Failure Patients:**
- **Amiodarone preferred:** Rate and rhythm control with minimal negative inotropic effect
- **Avoid beta-blockers:** In acute decompensated heart failure
- **Digoxin consideration:** For rate control in chronic heart failure

**Post-Cardiac Surgery:**
- **Amiodarone first-line:** Due to high efficacy in post-operative A-fib
- **Electrolyte optimization:** Magnesium and potassium repletion
- **Temporary pacing:** Available for bradycardia post-cardioversion

### **Interactive Decision Support Tools:**
**Rate Control Calculator:**
- **Weight-based dosing:** Automatic calculation for diltiazem and metoprolol
- **Titration guidance:** Based on heart rate response and hemodynamics
- **Safety alerts:** For contraindications and drug interactions

**CHA2DS2-VASc Calculator:**
- **Automated scoring:** Based on patient history and demographics
- **Risk stratification:** Color-coded recommendations for anticoagulation
- **HAS-BLED integration:** Bleeding risk assessment

**Rhythm Analysis Aid:**
- **Differential diagnosis:** Step-by-step rhythm identification
- **Treatment recommendations:** Algorithm-based therapeutic suggestions
- **Consultation triggers:** Automatic alerts for complex cases

### **Quality Improvement Metrics:**
- **Recognition time:** Goal <5 minutes from RRT activation to rhythm identification
- **Adenosine administration:** Goal <10 minutes for appropriate SVT
- **Rate control:** Goal heart rate <110 bpm within 30 minutes
- **Cardioversion success:** >90% success rate for appropriate indications

### **Medication Safety Program:**
- **Double verification:** For all high-risk medications (adenosine, amiodarone)
- **Allergy checking:** Automated screening for drug allergies
- **Interaction alerts:** Real-time monitoring for drug-drug interactions
- **Dosing verification:** Weight-based calculations with pharmacist oversight

## REFERENCE GUIDELINES
- **2020 AHA Guidelines for CPR and Emergency Cardiovascular Care**
- **2019 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation**
- **2017 AHA/ACC/HRS Guideline for the Management of Patients with Ventricular Arrhythmias**
- **Virtua Health System Tachycardia Protocol v2025**

**This protocol reflects current evidence-based ACLS and arrhythmia management guidelines optimized for rapid recognition, appropriate intervention, and excellent patient outcomes in the Virtua Voorhees RRT setting.**
